Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
153 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Escherichia coli Infections - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Escherichia Coli Infections - Pipeline Review, H2 2015', provides an overview of the Escherichia Coli Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Escherichia Coli Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Escherichia Coli Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Escherichia Coli Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Escherichia coli Infections Overview 9 Therapeutics Development 10 Pipeline Products for Escherichia coli Infections - Overview 10 Pipeline Products for Escherichia coli Infections - Comparative Analysis 11 Escherichia coli Infections - Therapeutics under Development by Companies 12 Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes 16 Escherichia coli Infections - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Escherichia coli Infections - Products under Development by Companies 20 Escherichia coli Infections - Products under Investigation by Universities/Institutes 23 Escherichia coli Infections - Companies Involved in Therapeutics Development 24 Adenium Biotech ApS 24 Arsanis Biosciences GmbH 25 AstraZeneca Plc 26 AvidBiotics Corp. 27 Bioorganic Research and Services S.A. 28 Cellceutix Corporation 29 Chiesi Farmaceutici SpA 30 Debiopharm International S.A. 31 Emergent BioSolutions Inc. 32 F. Hoffmann-La Roche Ltd. 33 GangaGen Inc. 34 GlaxoSmithKline Plc 35 Immuron Limited 36 Melinta Therapeutics, Inc 37 Microbiotix, Inc. 38 MicuRx Pharmaceuticals, Inc. 39 Mucosis B.V. 40 Navigen Pharmaceuticals, Inc. 41 Nosopharm SAS 42 Novabiotics Limited 43 Nymox Pharmaceutical Corporation 44 Pherecydes Pharma SA 45 Phico Therapeutics Limited 46 Procarta Biosystems Ltd 47 Sanofi Pasteur SA 48 Sealife PHARMA GMBH 49 Sequoia Sciences, Inc. 50 Soligenix, Inc. 51 Syntiron LLC 52 Tetraphase Pharmaceuticals Inc. 53 Trana Discovery, Inc. 54 Varinel, Inc. 55 Escherichia coli Infections - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Target 57 Assessment by Mechanism of Action 59 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 A-3APO - Drug Profile 65 AA-139 - Drug Profile 67 ACE-920 - Drug Profile 68 Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 69 ASN-4 - Drug Profile 70 AvR2-V10 - Drug Profile 72 BIZ-20131 - Drug Profile 74 BIZ-20132 - Drug Profile 75 BIZ-20133 - Drug Profile 76 BNT-006 - Drug Profile 77 CC-1807 - Drug Profile 78 Debio-1454 - Drug Profile 79 Drugs for Bacterial Infections - Drug Profile 80 dusquetide - Drug Profile 81 EcoXyn-4V - Drug Profile 83 enterotoxigenic escherichia coli vaccine - Drug Profile 84 Escherichia coli (whole cell) vaccine - Drug Profile 85 Escherichia coli vaccine - Drug Profile 86 Escherichia coli vaccine - Drug Profile 87 ETEC Vaccine - Drug Profile 88 ETEC vaccine - Drug Profile 89 EV-035 - Drug Profile 90 GN snare - Drug Profile 92 GN-4474 - Drug Profile 93 IMM-363 - Drug Profile 94 INX-201 - Drug Profile 95 JNJ-63871860 - Drug Profile 96 MBX-2319 - Drug Profile 97 MDN-0057 - Drug Profile 98 MRX-V - Drug Profile 100 NBTI-5463 - Drug Profile 101 NOSO-95179 - Drug Profile 102 NP-432 - Drug Profile 103 NXC-4720 - Drug Profile 104 Onc-72 - Drug Profile 105 PMX-1241 - Drug Profile 106 PMX-1278 - Drug Profile 107 PMX-1363 - Drug Profile 108 PMX-1405 - Drug Profile 109 PMX-247 - Drug Profile 110 PMX-843 - Drug Profile 111 PP-0121 - Drug Profile 112 Proteins for Infectious Diseases - Drug Profile 114 PT-4 - Drug Profile 115 Recombinant Protein for Escherichia Coli Infections - Drug Profile 116 RX-05 - Drug Profile 117 RXP-873 - Drug Profile 118 SE-1 - Drug Profile 119 Shigetec - Drug Profile 120 SLP-0901 - Drug Profile 121 SLP-0905 - Drug Profile 122 Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 123 Small Molecules for Bacterial Infections - Drug Profile 124 Small Molecules for Escherichia Coli Infections - Drug Profile 125 Small Molecules for Escherichia coli Infections - Drug Profile 126 Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 127 Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 128 Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 129 Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 130 Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 131 Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 132 Synthetic Peptides for Escherichia Coli Infections - Drug Profile 133 TP-6076 - Drug Profile 134 VAR-10100 - Drug Profile 135 Escherichia coli Infections - Recent Pipeline Updates 136 Escherichia coli Infections - Dormant Projects 143 Escherichia coli Infections - Discontinued Products 146 Escherichia coli Infections - Product Development Milestones 147 Featured News & Press Releases 147 Appendix 148 Methodology 148 Coverage 148 Secondary Research 148 Primary Research 148 Expert Panel Validation 148 Contact Us 148 Disclaimer 149
List of Tables
Number of Products under Development for Escherichia coli Infections, H2 2015 14 Number of Products under Development for Escherichia coli Infections - Comparative Analysis, H2 2015 15 Number of Products under Development by Companies, H2 2015 17 Number of Products under Development by Companies, H2 2015 (Contd..1) 18 Number of Products under Development by Companies, H2 2015 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2015 20 Comparative Analysis by Late Stage Development, H2 2015 21 Comparative Analysis by Clinical Stage Development, H2 2015 22 Comparative Analysis by Early Stage Development, H2 2015 23 Products under Development by Companies, H2 2015 24 Products under Development by Companies, H2 2015 (Contd..1) 25 Products under Development by Companies, H2 2015 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2015 27 Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H2 2015 28 Escherichia coli Infections - Pipeline by Arsanis Biosciences GmbH, H2 2015 29 Escherichia coli Infections - Pipeline by AstraZeneca Plc, H2 2015 30 Escherichia coli Infections - Pipeline by AvidBiotics Corp., H2 2015 31 Escherichia coli Infections - Pipeline by Bioorganic Research and Services S.A., H2 2015 32 Escherichia coli Infections - Pipeline by Cellceutix Corporation, H2 2015 33 Escherichia coli Infections - Pipeline by Chiesi Farmaceutici SpA, H2 2015 34 Escherichia coli Infections - Pipeline by Debiopharm International S.A., H2 2015 35 Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc., H2 2015 36 Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 37 Escherichia coli Infections - Pipeline by GangaGen Inc., H2 2015 38 Escherichia coli Infections - Pipeline by GlaxoSmithKline Plc, H2 2015 39 Escherichia coli Infections - Pipeline by Immuron Limited, H2 2015 40 Escherichia coli Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015 41 Escherichia coli Infections - Pipeline by Microbiotix, Inc., H2 2015 42 Escherichia coli Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015 43 Escherichia coli Infections - Pipeline by Mucosis B.V., H2 2015 44 Escherichia coli Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015 45 Escherichia coli Infections - Pipeline by Nosopharm SAS, H2 2015 46 Escherichia coli Infections - Pipeline by Novabiotics Limited, H2 2015 47 Escherichia coli Infections - Pipeline by Nymox Pharmaceutical Corporation, H2 2015 48 Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H2 2015 49 Escherichia coli Infections - Pipeline by Phico Therapeutics Limited, H2 2015 50 Escherichia coli Infections - Pipeline by Procarta Biosystems Ltd, H2 2015 51 Escherichia coli Infections - Pipeline by Sanofi Pasteur SA, H2 2015 52 Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H2 2015 53 Escherichia coli Infections - Pipeline by Sequoia Sciences, Inc., H2 2015 54 Escherichia coli Infections - Pipeline by Soligenix, Inc., H2 2015 55 Escherichia coli Infections - Pipeline by Syntiron LLC, H2 2015 56 Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 57 Escherichia coli Infections - Pipeline by Trana Discovery, Inc., H2 2015 58 Escherichia coli Infections - Pipeline by Varinel, Inc., H2 2015 59 Assessment by Monotherapy Products, H2 2015 60 Number of Products by Stage and Target, H2 2015 62 Number of Products by Stage and Mechanism of Action, H2 2015 64 Number of Products by Stage and Route of Administration, H2 2015 66 Number of Products by Stage and Molecule Type, H2 2015 68 Escherichia coli Infections Therapeutics - Recent Pipeline Updates, H2 2015 140 Escherichia coli Infections - Dormant Projects, H2 2015 147 Escherichia coli Infections - Dormant Projects (Contd..1), H2 2015 148 Escherichia coli Infections - Dormant Projects (Contd..2), H2 2015 149 Escherichia coli Infections - Discontinued Products, H2 2015 150
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
